Hangzhou Bioer Technology

Bioer IPO: Currently Holding Strong but Would Growth Rates Sustain Post-COVID?

Equity Capital Markets
213 Views, 13 Jan 2022 21:38
EXECUTIVE SUMMARY
  • Bioer designs, manufactures and sells three categories of PCR products: instruments, reagents and consumables. With the spread of COVID-19, the company experienced strong growth in revenue and margin improvements. 
  • The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of around US$200m
  • Strong growth in Bioer’s revenue over the last two years was predominantly driven by the spread of COVID-19. We are concerned on the company’s ability to maintain its revenues post-COVID.
detail (9-minute read)
WHAT’S TRENDING
logo
Logo
Top 5%
Shifara Samsudeen, ACMA, CGMA
Equity Analyst
LightStream Research
JapanIndustrialsEquity Bottom-UpEquity Capital Markets

A chartered management accountant with more than 10 years of rich experience in investment research and financial analys... 

x